Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Celldex Therapeutics, Inc. (CLDX)

34.20 +0.91 (+2.73%)
As of 12:08:59 PM EDT. Market Open.
Trade CLDX on Coinbase
Chart Range Bar
Loading chart for CLDX
  • Previous Close 33.29
  • Open 33.15
  • Bid 29.04 x 100
  • Ask 38.87 x 100
  • Day's Range 33.15 - 34.50
  • 52 Week Range 17.85 - 35.79
  • Volume 201,338
  • Avg. Volume 1,037,542
  • Market Cap (intraday) 2.683B
  • Beta (5Y Monthly) 1.20
  • PE Ratio (TTM) --
  • EPS (TTM) -3.90
  • Earnings Date (est.) May 7, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 57.00

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.

www.celldex.com

198

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News: CLDX

View More

Performance Overview: CLDX

Trailing total returns as of 4/27/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CLDX
25.92%
S&P 500 (^GSPC)
4.61%

1-Year Return

CLDX
74.76%
S&P 500 (^GSPC)
29.60%

3-Year Return

CLDX
7.78%
S&P 500 (^GSPC)
73.16%

5-Year Return

CLDX
8.78%
S&P 500 (^GSPC)
71.04%

Earnings Trends: CLDX

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY25
Revenue 121k
Earnings -81.32M

Q1

FY25

Q2

FY25

Q3

FY25

Q4

FY25

-80M
-60M
-40M
-20M
0

Analyst Insights: CLDX

View More

Analyst Price Targets

34.00
57.00 Average
34.20 Current
90.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 4/20/2026
Analyst Barclays
Rating Action Upgrade
Rating Overweight
Price Action Raises
Price Target 24 -> 45

Statistics: CLDX

View More

Valuation Measures

Annual
As of 4/24/2026
  • Market Cap

    2.61B

  • Enterprise Value

    2.10B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.43k

  • Price/Book (mrq)

    4.95

  • Enterprise Value/Revenue

    1.36k

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -26.12%

  • Return on Equity (ttm)

    -40.62%

  • Revenue (ttm)

    1.54M

  • Net Income Avi to Common (ttm)

    -258.76M

  • Diluted EPS (ttm)

    -3.90

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    518.57M

  • Total Debt/Equity (mrq)

    0.44%

  • Levered Free Cash Flow (ttm)

    -125.54M

Compare To: CLDX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights: CLDX

Fair Value

34.20 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: